陈淼;张华;王晓旭;程向前;安冬青;

• 1:新疆医科大学第四临床医学院
• 2:新疆医科大学
• 3:新疆名医名方与特色方剂学实验室

摘要(Abstract)：

天香丹以"通补开泄法"为理论依据研制而成,具有化痰散结、和血通络、益气补虚的功效,临床多用于治疗秽浊痰阻型冠状动脉粥样硬化性心脏病(简称冠心病)。大量基础实验和临床研究表明,天香丹通过改善血管内皮功能、抗感染、调节血脂、稳定斑块、改善心功能等方面而发挥作用,以多靶点、多层次、多成分的优势治疗冠状动脉粥样硬化性心脏病,取得显著疗效。目前,天香丹对血流动力学的影响尚不明确,且缺乏大样本量的多中心临床研究。今后,需开展高质量、大样本的随机对照研究,加强对血流动力学影响的研究,进一步阐明天香丹的作用机制,为临床应用提供更多的科学依据。

关键词(KeyWords)： 天香丹;冠状动脉粥样硬化性心脏病;秽浊痰阻证

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金地区科学基金项目(81760843)

作者(Author): 陈淼;张华;王晓旭;程向前;安冬青;

Email:

DOI: 10.16367/j.issn.1003-5028.2021.02.0068

参考文献(References)：

• [1] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
• [2] YANG W J,LIU C,GU Z Y,et al.Protective effects of acacetin isolated from Ziziphora clinopodioides Lam.(Xintahua) on neonatal rat cardiomyocytes[J].Chin Med,2014,9(1):28.
• [3] 李慧,安冬青,谢晓柳,等.249例冠心病患者冠脉造影的临床特征分析[J].中西医结合心脑血管病杂志,2011,9(6):651-653.
• [4] SULTAN C S,WEITNAUER M,TURINSKY M,et al.Functional association of a CD40 gene single-nucleotide polymorphism with the pathogenesis of coronary heart disease[J].Cardiovasc Res,2020,116(6):1214-1225.
• [5] 赵姣姣,董建业,柴丽丽,等.冠心病心绞痛中医证型分布与中药用药规律系统综述[J].实用中医内科杂志,2017,31(2):1-5.
• [6] NIU J,HAN X,QI H,et al.Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction[J].Exp Ther Med,2016,12(1):475-479.
• [7] 安冬青,胡金霞,赵明芬,等.天香丹对冠心病病人血管内皮生长因子及相关因子的影响[J].中西医结合心脑血管病杂志,2007,5(8):662-664.
• [8] 庞辉群,安冬青,胡金霞,等.通补开泄法促进冠心病患者血管新生的研究[J].山东中医药大学学报,2008,32(6):462-465.
• [9] CAPRA V B,CK M,ANGIOLILLO D J,et al.Impact of vascular thromboxane prostanoid receptor activation on hemostasis,thrombosis,oxidative stress,and inflammation[J].J Thromb Haemost,2014,12(2):126-137.
• [10] NAKAHATA N.Thromboxane A2:physiology/pathophysiology,cellular signal transduction and pharmacology[J].Pharmacol Ther,2008,118(1):18-35.
• [11] 安冬青,周铭心,张晓天,等.天香丹对心肌缺血大鼠血栓形成及心肌细胞结构的影响[J].新疆医科大学学报,2007,30(5):434-437.
• [12] MUDAU M,GENIS A,LOCHNER A,et al.Endothelial dysfunction:the early predictor of atherosclerosis[J].Cardiovasc J Afr,2012,23(4):222-231.
• [13] KANAAN G N,HARPER M E.Cellular redox dysfunction in the development of cardiovascular diseases[J].Biochim Biophys Acta Gen Subj,2017,1861(11):2822-2829.
• [14] 李必旭,安冬青,张焱,等.天香丹对冠脉结扎大鼠血浆NO、ET的影响[J].中医药研究,2002,14(1):41-42.
• [15] 安冬青,施建明,姚海洪.天香丹对冠心病血管调节肽、血栓素A2/前列环素影响的临床与实验研究[C].成都:第三届心脏学会、第六届心功能学会及心功能杂志创刊10周年学术会议论文集,1996:118.
• [16] 张焱,安冬青,李必旭.天香丹治气虚血瘀证冠心病临床观察[J].江西中医药,2002,33(3):6-7.
• [17] 牛力军,康福信,甫拉提·吐尔逊.天香丹对大鼠心肌缺血再灌注损伤的保护作用研究[J].新疆医科大学学报,2008,31(2):168-170.
• [18] 陈继红,冉亚军,王晓峰.天香丹颗粒对血运重建患者的生理及心理影响[J].西部中医药,2016,29(5):81-84.
• [19] 李静茹,席耀明,王晓峰,等.天香丹颗粒对冠脉搭桥术后患者临床疗效的影响[J].中华中医药杂志,2011,26(9):2129-2131.
• [20] 梁维维.用天香丹胶囊对行冠脉搭桥术的患者实施术后康复治疗的效果探究[J].当代医药论丛,2014,12(19):27-28.
• [21] CHU L M,LASSALETTA A D,ROBICH M P,et al.Resveratrol in the prevention and treatment of coronary artery disease[J].Curr Atheroscler Rep,2011,13(6):439-446.
• [22] 孙龙飞,谢晓柳,古丽加玛力·尼亚孜,等.天香丹对冠心病稳定型心绞痛病人临床疗效及血清中炎性因子IL-1β和TNF-α的影响[J].中西医结合心脑血管病杂志,2019,17(3):334-337.
• [23] 杨建梅,安冬青,王晓峰,等.天香丹颗粒治疗冠心病心绞痛33例[J].上海中医药大学学报,2006,20(2):29-31.
• [24] 张玲,安冬青.天香丹颗粒对不稳定性心绞痛的相关炎性因子的影响[J].新疆中医药,2005,23(3):22-24.
• [25] 冉亚军,陈继红,安冬青.足浴天香丹对冠心病患者的血管功能及炎性因子调节作用[J].中国中医基础医学杂志,2012,18(12):1366-1367.
• [26] SUN L F,AN D Q,NIYAZI G L,et al.Effects of Tianxiangdan Granule treatment on atherosclerosis via NF-κB and p38 MAPK signaling pathways[J].Mol Med Rep,2018,17(1):1642-1650.
• [27] 王思静,张华,马学宽,等.天香丹对动脉粥样硬化ApoE-/-小鼠IL-6、IL-10表达的影响[J].新疆医科大学学报,2019,42(7):930-933.
• [28] 张华,王思静,马学宽,等.新塔花水提物对ApoE-/-动脉粥样硬化模型小鼠血清中IL-6、IL-10表达的影响[J].中华中医药杂志,2019,34(7):3258-3261.
• [29] MARTINEZ-LEMUS L A,GALIANES E L.Matrix metalloproteinases and small artery remodeling[J].Drug Discov Today Dis Models,2011,8(1):21-28.
• [30] Krizkova S,Zitka O,Masarik M,et al.Clinical importance of matrix metalloproteinases[J].Bratisl Lek Listy,2011,112(8):435-440.
• [31] 马文慧,安冬青,古丽加玛力·尼亚孜,等.天香丹对动脉粥样硬化秽浊痰阻证ApoE-/-小鼠斑块内MMP-9和TIMP-1表达的影响[J].中国中医基础医学杂志,2015,21(8):943-945,1039.
• [32] 张华,王思静,邢科,等.新塔花对ApoE-/-小鼠动脉粥样硬化模型中TLR4/NF-κb信号通路的影响[J].中国中医急症,2019,28(4):576-578,589.
• [33] SUWA S,OGITA M,MIYAUCHI K,et al.Impact of lipoprotein (a) on long-term outcomes in patients with coronary artery disease treated with statin after a first percutaneous coronary intervention[J].J Atheroscler Thromb,2017,24(11):1125-1131.
• [34] 刘伟,安冬青,郭龙龙,等.天香丹治疗秽浊痰阻证冠心病的临床观察[J].中西医结合心脑血管病杂志,2017,15(10):1211-1212.
• [35] KURIAN G A,RAJAGOPAL R,VEDANTHAM S,et al.The role of oxidative stress in myocardial ischemia and reperfusion injury and remodeling:revisited[J].Oxidative Med Cell Longev,2016,25(5):1656450.
• [36] 殷建明,朱江丽,刘琴,等.天香丹颗粒对冠心病心绞痛患者血清中T-SOD GSH-Px、MDA、LD的影响[J].中国中医药信息杂志,2003,10(7):13-15.
• [37] 焦玉洁,安冬青,李方帅,等.天香丹对ApoE(-/-)基因敲除小鼠动脉粥样硬化的影响[J].湖南中医杂志,2012,28(3):128-130.
• [38] 马文慧,安冬青.天香丹对动脉粥样硬化秽浊痰阻证ApoE-/-小鼠的实验研究[J].中国中医急症,2015,24(3):377-379,383.
• [39] 贾颖.超声二维应变成像在冠心病心肌收缩运动异常中的应用[J].影像研究与医学应用,2019,3(3):145-146.
• [40] 郑静.天香丹对冠心病患者应变率的影响[D].乌鲁木齐:新疆医科大学,2007.
• [41] 安冬青.天香丹治疗冠心病及对心肌线粒体ATPase、MVC、MVD影响的实验研究[D].乌鲁木齐:新疆医科大学,2007.
• [42] JOSé EK VITORIN,TASHA K PONTIFEX,JANIS M BURT.Determinants of Cx43 channel gating and permeation:the amino Terminus[J].Biophys J,2016,110(1):127-140.
• [43] LIU Y,ZOU J,LIU X,et al.MicroRNA-138 attenuates myocardial ischemia reperfusion injury through inhibiting mitochondria-mediated apoptosis by targeting HIF1-Α[J].Exp Ther Med,2019,18(5):3325-3332.
• [44] BARTEL D P.MicroRNAs:target recognition and regulatory functions[J].Cell,2009,136(2):215-233.
• [45] RAO P K,TOYAMA Y,CHIANG H R,et al.Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure[J].Circ Res,2009,105(6):585-594.
• [46] CZECH B,HANNON G J.Small RNA sorting:matchmaking for Argonautes[J].Nat Rev Genet,2011,12(1):19-31.
• [47] LI Q,CHENG K,WANG A Y,et al.microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway[J].Biomed Pharmacother,2019,116(8):109007.
• [48] ZHANG Q,KANDIC I,KUTRYK M J.Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease[J].Biochem Biophys Res Commun,2011,405(1):42-46.
• [49] 郭龙龙,安冬青,刘伟,等.天香丹干预冠心病秽浊痰阻证病人血浆miR-126表达水平变化研究[J].中西医结合心脑血管病杂志,2017,15(22):2850-2852.
• [50] 郭龙龙.天香丹干预冠心病秽浊痰阻证患者microRNA-126和microRNA-155表达水平的研究[D].乌鲁木齐:新疆医科大学,2018.
• [51] WU X Y,FAN W D,FANG R,et al.Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65[J].J Cell Biochem,2014,115(11):1928-1936.
• [52] 渠乐,周云.足浴天香丹在慢性心力衰竭中的应用研究[J].中医临床研究,2012,4(6):84,86.